Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Bill Haddad

1664 posts
Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • News
  • Stock Split

Palo Alto Networks Board Of directors Approves Three-For-One Stock Split

By Bill Haddad
August 22, 4:11 PM
Stock Split Authorization Palo Alto Networks announced that the board of directors has approved and declared a three-for-one split of Palo Alto Networks' common stock in the form of a stock dividend. Each

PANW

Read More
1 minute read
  • Guidance
  • News

Palo Alto Networks Sees FY23 Adj. EPS $9.40-$9.50, Sales $6.85B-$6.90B vs $6.74B Est.

By Bill Haddad
August 22, 4:07 PM
For the fiscal year 2023, we expect: Total billings in the range of $8.95 billion to $9.05 billion, representing year-over-year growth of between 20% and 21%. Total revenue in the range

PANW

Read More
2 minute read
  • News

E-Home Household Service Holdings Says Is Anticipated To Report Over 3M Registered Members As Of Jun. 30 2022

By Bill Haddad
August 22, 9:09 AM
E-Home Household Service Holdings Limited (NASDAQ:EJH) (the "Company" or "E-Home"), a provider of integrated household services in China, today announced unaudited preliminary operation matric for

EJH

Read More
1 minute read
  • Management
  • News

Enfusion Appoints Oleg Movchan Interim Chief Executive Officer

By Bill Haddad
August 22, 8:37 AM
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-based investment management software and services, today announced that its Board of Directors (the "Board") has

ENFN

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

Salarius Pharmaceuticals Adds Two Mayo Clinic Sites To Its Ongoing Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing’s Sarcoma And FET-Rearranged Sarcomas

By Bill Haddad
August 22, 8:33 AM
Expands Trial to 17 U.S. Sites and 25 Locations  Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a

SLRX

Read More
1 minute read
  • Asset Sales
  • News

WillScot Mobile Mini Holdings Announces Agreement To Divest Tank And Pump Segment To Kinderhook Industries For Enterprise Value Of ~$32<

By Bill Haddad
August 22, 8:31 AM
WillScot Mobile Mini Holdings Corp. ("WillScot Mobile Mini Holdings" or the "Company") (NASDAQ:WSC), the North American leader in innovative flexible workspace and portable storage solutions, today

WSC

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Kronos Bio Announces First Patient Dosed In Phase 1b/2 Clinical Trial Of Lanraplenib In Combination With Gilteritinib In Acute Myeloid Leukemia

By Bill Haddad
August 22, 8:08 AM
Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in

KRON

Read More
1 minute read
  • Legal
  • News

BGC Wins Lawsuit Challenging Purchase Of Berkeley Point

By Bill Haddad
August 22, 8:05 AM
Judge Determines That Purchase Price Was Entirely Fair to Shareholders and Board Members Acted Appropriately NEW YORK, Aug. 22, 2022 /PRNewswire/ -- BGC Partners, Inc. (NASDAQ:BGCP) ("BGC"), a

BGCP

Read More
1 minute read
  • Earnings
  • News

Jaguar Health Q2 EPS $(0.12) Beats $(0.22) Estimate, Sales $2.92M Miss $3.10M Estimate

By Bill Haddad
August 22, 8:03 AM
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 60 percent increase over losses of $(0.30) per share from the

JAGX

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Minerva Neurosciences Submits New Drug Application To FDA For Roluperidone For Treatment Of Negative Symptoms In Patients With Schizophrenia

By Bill Haddad
August 22, 8:01 AM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the company has

NERV

Posts pagination

Previous 1 … 95 96 97 … 167 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service